Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-16 4:00 pm Purchase | 2020-12-31 | 13G | Keros Therapeutics, Inc. KROS | Logos Global Master Fund LP | 450,000 1.900% | 450,000 (New Position) | Filing History |
| 2021-02-16 10:56 am Sale | 2020-12-31 | 13G | Keros Therapeutics, Inc. KROS | Foresite Capital Fund IV L.P. | 1,412,705 6.100% | -15,366 (-1.08%) | Filing History |
| 2021-02-10 4:48 pm Sale | 2021-01-31 | 13G | Keros Therapeutics, Inc. KROS | RA Capital Management, L.P. | 0 0.000% | -1,875,000 (Position Closed) | Filing History |
| 2021-02-10 4:31 pm Purchase | 2020-12-31 | 13G | Keros Therapeutics, Inc. KROS | RA Capital Management, L.P. | 1,875,000 8.100% | 1,875,000 (New Position) | Filing History |
| 2021-02-08 10:25 am Sale | 2021-02-05 | 13G | Keros Therapeutics, Inc. KROS | FMR LLC | 2,644,620 11.411% | -381,261 (-12.60%) | Filing History |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Keros Therapeutics, Inc. KROS | BlackRock Inc. BLK | 1,199,201 5.200% | 1,199,201 (New Position) | Filing History |
| 2020-12-17 06:48 am Unchanged | 2020-12-17 | 13D | Keros Therapeutics, Inc. KROS | Arkin Moshe | 2,036,140 8.790% | 0 (Unchanged) | Filing History |
| 2020-11-25 06:31 am Unchanged | 2020-11-17 | 13D | Keros Therapeutics, Inc. KROS | Arkin Moshe | 2,036,140 8.790% | 0 (Unchanged) | Filing History |
| 2020-11-20 4:32 pm Unchanged | 2020-11-19 | 13D | Keros Therapeutics, Inc. KROS | ORBIMED ADVISORS LLC | 1,268,734 5.500% | 0 (Unchanged) | Filing History |
| 2020-11-10 10:27 am Purchase | 2020-11-09 | 13G | Keros Therapeutics, Inc. KROS | FMR LLC | 3,025,881 14.999% | 3,025,881 (New Position) | Filing History |
| 2020-08-31 1:35 pm Purchase | 2020-08-20 | 13G | Keros Therapeutics, Inc. KROS | Logos Global Management LP | 1,350,000 6.700% | 1,350,000 (New Position) | Filing History |
| 2020-04-23 4:00 pm Purchase | 2020-04-13 | 13D | Keros Therapeutics, Inc. KROS | Pontifax Management 4 G.P. (2015) Ltd. | 4,734,507 23.600% | 4,734,507 (New Position) | Filing History |
| 2020-04-20 1:14 pm Purchase | 2020-04-08 | 13D | Keros Therapeutics, Inc. KROS | Arkin Moshe | 2,036,140 10.600% | 2,036,140 (New Position) | Filing History |
| 2020-04-17 4:07 pm Purchase | 2020-04-08 | 13D | Keros Therapeutics, Inc. KROS | ORBIMED ADVISORS LLC | 1,268,734 6.300% | 1,268,734 (New Position) | Filing History |
| 2020-04-15 4:30 pm Purchase | 2020-04-08 | 13G | Keros Therapeutics, Inc. KROS | Foresite Capital Fund IV L.P. | 1,428,071 7.100% | 1,428,071 (New Position) | Filing History |